Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $60.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Ryskin has given his Buy rating due to a combination of factors including Guardant Health’s strong financial performance and strategic positioning. The company reported impressive first-quarter results for 2025, with total revenues surpassing expectations and reaching $203 million, driven by significant growth in oncology sales and improved cost efficiencies. This financial strength is further underscored by the company’s ability to increase its full-year sales guidance, reflecting confidence in continued growth.
Additionally, Guardant Health’s leadership in the liquid biopsy market and its attractive valuation contribute to the positive outlook. The company is poised for long-term growth with upcoming data readouts and potential advancements in its Shield product line, which could enhance its market position. These factors, combined with a solid price objective of $60 based on a discounted cash flow analysis, support the Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue